Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | CTNNB1 | P35222 | 13/20 | 0.58 |
| ▸ | WNT3A | P56704 | 13/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979723 | 0.84 | CTNNB1 (0.70) | NPC1RAB9ACTNNB1WNT3AHDAC8 | |
| SCHEMBL15979736 | 0.84 | NPC1 (0.76) | NPC1RAB9ACTNNB1WNT3AHDAC8 | |
| SCHEMBL15979725 | 0.83 | CTNNB1 (0.58) | NPC1RAB9ACTNNB1WNT3AHDAC8 | |
| SCHEMBL15979734 | 0.82 | CTNNB1 (0.71) | NPC1RAB9ACTNNB1WNT3AHDAC8 | |
| SCHEMBL15988791 | 0.81 | CTNNB1 (0.70) | NPC1CTNNB1WNT3AKMT2A | |
| SCHEMBL15980081 | 0.79 | CTNNB1 (0.63) | NPC1CTNNB1WNT3AHDAC8HDAC1 | |
| SCHEMBL15979726 | 0.78 | MAPT (0.56) | NPC1RAB9ARXFP1KMT2A | |
| SCHEMBL18340892 | 0.78 | L3MBTL1 (0.50) | NPC1RAB9ACTNNB1WNT3ARXFP1 | |
| SCHEMBL15979731 | 0.78 | CTNNB1 (0.65) | NPC1RAB9ACTNNB1WNT3AHDAC8 | |
| SCHEMBL5504427 | 0.78 | RAB9A (1.00) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220087917-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2022-03-24 | — | — | US | disclosed |
| US-11077046-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200222295-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
| US-10434052-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| WO-2016029021-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | SAMUMED, LLC (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2014-08-28 | — | — | US | disclosed |
| WO-2014130869-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | SAMUMED, LLC (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077046-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | GLA, DGKG, DGKA | NPC1 4073/4885RAB9A 2923/4885CTNNB1 1789/4885 |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | NPC1 4073/4885RAB9A 2923/4885CTNNB1 1789/4885 |
| US-20220087917-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | NPC1 4073/4885RAB9A 2923/4885CTNNB1 1789/4885 |
| US-20200222295-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | NPC1 4073/4885RAB9A 2923/4885CTNNB1 1789/4885 |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | NPC1 1560/4885RAB9A 825/4885CTNNB1 6/4885 |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | NPC1 4073/4885RAB9A 2923/4885CTNNB1 1789/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | NPC1 3947/4885RAB9A 2448/4885CTNNB1 1475/4885 |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | NPC1 1560/4885RAB9A 825/4885CTNNB1 6/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | NPC1 1450/4885RAB9A 845/4885CTNNB1 5/4885 |
| US-10434052-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | GLA, DGKA, DGKG | NPC1 4077/4885RAB9A 2486/4885CTNNB1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.